Core Insights - The Watsons Health and Beauty Awards (HWB) 2025 announced that Winona won the Best Brand Award and its Clear Sunscreen won the Best Product Award, marking a significant achievement for the brand in the sensitive skin care market [1][3] Group 1: Brand Performance - Winona has maintained its position as the number one brand in sensitive skin care sales in China from 2020 to 2024, as certified by international agency, Sullivan [2][3] - The brand's success is attributed to its unique approach of developing skin care products based on clinical research and consumer needs, establishing a strong reputation and trust among consumers [2][4] Group 2: Product Innovation - Winona's new generation of star product, the second-generation Winona Special Care Cream, represents a significant iteration after 13 years, utilizing breakthrough technology for effective skin repair [3][4] - The Clear Sunscreen, which has been on the market for ten years, is recognized for its gentle formulation and effectiveness, having been rigorously tested for safety and efficacy [4][5] Group 3: Market Strategy - Winona's "Sensitive Skin PLUS" strategy focuses on addressing specific needs within the sensitive skin demographic, creating a diverse product line that includes specialized creams and sunscreens [4][5] - The brand has achieved significant recognition in the market, ranking in the top 10 sales at Watsons and demonstrating strong consumer approval [3][5] Group 4: Future Outlook - Winona aims to lead the sensitive skin care sector with medical-grade standards, continuously enhancing consumer trust and satisfaction while striving for health and beauty goals [7]

Group 1 - The core achievement of Betaini Group's brand Winona is being recognized as the top-selling sensitive skin care brand in China for five consecutive years (2020-2024) by Frost & Sullivan, highlighting the effectiveness of its medical research-driven skincare standards [1] - Winona's leading position is attributed to its dual-engine strategy of "medical genetics + plant technology," utilizing over 6,500 medicinal plant resources from Yunnan and establishing a comprehensive solution for sensitive skin through the unique "NUTE principle" [1] - Betaini has successfully registered 16 new cosmetic plant ingredients, leading the domestic beauty industry in registration volume, and plans to invest 337 million yuan in R&D in 2024, maintaining an annual R&D investment growth rate of over 5% for three consecutive years [1] Group 2 - Winona was selected as the only dermatological brand in the first batch of "Chinese Consumer Brands" by the Ministry of Industry and Information Technology, filling a gap in the national brand matrix, while Betaini was included in the first "100 Benchmark Brands for Chinese Brand Internationalization" alongside Huawei and BYD [2] - Betaini has established a multinational R&D network across China, France, and Japan, with a Southeast Asia headquarters in Bangkok, and has successfully entered sales channels in Thailand and Hong Kong [3] - The combination of three authoritative certifications reinforces the "medical genetics + plant technology" model and positions Chinese efficacy skincare brands for global competition, emphasizing scientific credibility [3]

Group 1: Business Strategy and Performance - The company plans to enhance the performance of brands ZA and Pomei by strictly executing operational budgets, controlling marketing ROI, and reducing ineffective expenditures to lower sales expense ratios [2] - In 2025, the company will focus on brand building, member operations, and overall collaborative growth, emphasizing its core strengths and enhancing organizational transformation [5] - The company aims to maintain its leadership in the sensitive skin care market by deepening the brand genes of "skin medicine," "plant technology," and "evidence-based medicine" [5] Group 2: Market Expansion and Product Development - The company will continue to explore overseas markets to improve profitability and support its main brand through collaborative efforts with its R&D team [6] - A new product, Silver Core Cream, has been launched targeting anti-aging needs for sensitive skin, featuring a proprietary ingredient aimed at combating aging factors [4] - The company plans to enhance online traffic conversion efficiency through a dual focus strategy on product and channel optimization [4] Group 3: Financial Management and Investor Relations - The company acknowledges the impact of various factors on stock price and emphasizes the importance of communication with investors through various market activities [3] - Management fees increased by 56% year-on-year, exceeding the industry average of 4-6%, prompting the company to implement measures to control expenses [7] - The company has established a market value management system to improve operational performance and provide better returns to investors [7] Group 4: Consumer Feedback and Product Quality - The company is committed to improving customer service and addressing feedback regarding product quality and after-sales support [8] - Concerns were raised about the quality of promotional gifts, leading the company to consider enhancing the quality of these items [3] - The company is focused on maintaining a balance between cost considerations and customer expectations for product quality [3]

Investment Rating - The report maintains a "Recommended" rating for the company, with a target price based on projected earnings growth and valuation metrics [4][5]. Core Insights - The company reported a revenue of 5.736 billion yuan for 2024, reflecting a year-on-year growth of 3.87%. However, the net profit attributable to shareholders decreased by 33.53% to 503 million yuan [2][5]. - The main revenue source is the brand "Winona," which saw a revenue decline of 5.45% to 4.909 billion yuan, while "Winona Baby" and "Aikeman" experienced significant growth of 34.03% and 65.59%, respectively [2][4]. - The gross margin for 2024 was 73.74%, with a slight decrease of 0.16 percentage points year-on-year. The net profit margin decreased by 4.93 percentage points to 8.77% [3][4]. Financial Performance Summary - Revenue projections for 2025, 2026, and 2027 are 6.285 billion yuan, 7.153 billion yuan, and 8.146 billion yuan, respectively, with growth rates of 9.6%, 13.8%, and 13.9% [5][7]. - The net profit attributable to shareholders is expected to recover to 700 million yuan in 2025, with a growth rate of 39.2%, followed by 856 million yuan in 2026 and 1.059 billion yuan in 2027 [5][7]. - The report indicates an increase in operating expenses, with sales, management, and R&D expense ratios rising significantly in recent quarters [3][4]. Brand Strategy and Market Position - The company is expanding its market presence with a multi-brand strategy, focusing on the main brand "Winona" and introducing new products in the sensitive skin segment [4]. - The launch of the "Winona 2.0" strategy aims to enhance brand positioning and product offerings, which is expected to drive long-term growth [4][5].

Core Viewpoint - The company reported disappointing financial results for 2024 and Q1 2025, with revenue growth stagnating and significant declines in net profit due to asset impairment losses and increased marketing expenses [1][3]. Financial Performance - For 2024, the company achieved revenue of 5.74 billion, a year-on-year increase of 3.9%, but net profit attributable to shareholders fell by 33.5% to 500 million [1]. - In Q1 2025, revenue was 950 million, down 13.5% year-on-year, with net profit dropping 84.0% to 28 million [1]. - The decline in net profit was primarily attributed to underperformance of Yujing Investment, leading to asset impairment losses, alongside increased sales expenses from brand promotion and online channel investments [1]. Development Trends - The main brand, Winona, focused on core products, with revenue declining by 5.5% to 4.9 billion in 2024, while sub-brands showed growth, with Winona Baby increasing by 34.0% to 200 million and AOXMED rising by 65.6% to 60 million [2]. - Online sales grew by 10.1% in 2024, with Douyin channel sales up 31%, while offline sales declined [2]. Profitability and Cost Management - Gross margin improved significantly in Q1 2025, reaching 77.5%, up 5.4 percentage points year-on-year, due to a focus on core products and price stability [3]. - However, the sales expense ratio increased, with a rise of 2.7 percentage points to 50.0% in 2024 and 9.3 percentage points to 56.0% in Q1 2025, driven by increased promotional and membership operation costs [3]. - The company faced asset impairment losses of 90 million and 25 million from goodwill and intangible assets, respectively, impacting net profit margins [3]. Strategic Outlook - The company plans to streamline its product matrix and optimize channel strategies, focusing on reducing promotional intensity and improving online operational efficiency [4]. - There is an emphasis on expanding the second-tier brands like Winona Baby and AOXMED, with attention on future operational improvements [4]. Earnings Forecast and Valuation - The company has lowered its net profit forecasts for 2025 and 2026 by 22% and 17% to 670 million and 790 million, respectively [5]. - The current stock price corresponds to a P/E ratio of 26x for 2025 and 22x for 2026, with a target price adjustment down by 12% to 53 yuan, indicating a potential upside of 31% [5].

Core Insights - Yunnan Betaini Biotechnology Group Co., Ltd. reported steady performance growth in its 2024 annual report, achieving significant results in its multi-brand strategy [1] Financial Performance - The company achieved an operating revenue of 5.736 billion yuan in 2024, representing a year-on-year increase of 3.87% [1][2] - The net profit attributable to shareholders decreased by 33.53% to 503 million yuan due to multiple factors [1][2] - Total assets reached 8.304 billion yuan, a 10% increase from the previous year [2] - The net asset attributable to shareholders increased by 3% to 6.050 billion yuan [2] - The basic and diluted earnings per share were both 1.20 yuan, down 32% from the previous year [2] Brand Strategy - The company continued to deepen its multi-brand strategy, focusing on the "Winona" brand while promoting other brands such as "Winona Baby," "AOXMED," "Beforteen," "Za," and "PURE&MILD" [1][3] - The main brand "Winona" launched a 2.0 strategy, upgrading its brand concept to "Researching Sensitive Skin," reinforcing its leading position in the sensitive skin care sector [1] Brand Performance - "Winona Baby" focused on solutions for infant eczema, achieving sales of 201 million yuan, a growth of 34.03% [3] - "AOXMED" specialized in skin youthfulness, with sales nearing 60 million yuan, a growth of 65.59% [3] - "Beforteen" established a brand image through targeted marketing and private domain operations [3] Research and Development - The company invested 337 million yuan in R&D in 2024, maintaining an average annual investment intensity of over 5% for three consecutive years [5] - The company registered 9 new cosmetic raw materials and accumulated 12, with 43 self-developed cosmetic and 9 food raw materials [5] - The company obtained 88 patents and published 107 SCI papers, receiving international innovation awards [5] Operational and Social Responsibility - The company made significant progress in channel construction, supply chain optimization, and social responsibility [5] - It adopted an omnichannel strategy to cover a broader consumer base and improved operational efficiency through supply chain optimization and digitalization [5] - The company actively participated in public welfare projects, providing scientific skin care and sun protection support to residents in remote areas [5] Future Outlook - The company aims to continue its mission of "building a Chinese skin health ecosystem," focusing on brand building, member operations, and collaborative growth [5]

Investment Rating - The investment rating for the company is "Buy" with a target price not specified [5] Core Views - The company experienced a temporary pressure on performance, but the makeup business showed remarkable growth [1] - The skincare segment's revenue decreased by 1.41% year-on-year, while the makeup segment's revenue surged by 226.48% [3] - The company is focusing on multi-brand development with Winona as the core brand, aiming to enhance customer value through a combination strategy of single products and sets [4] Financial Performance Summary - For 2024, the company reported a revenue of 5.736 billion yuan, a year-on-year increase of 3.87%, and a net profit attributable to the parent company of 503 million yuan, a decrease of 33.53% [1] - The gross profit margin for 2024 was 73.74%, a slight decrease of 0.16 percentage points year-on-year [2] - The company’s revenue for Q1 2025 was 949 million yuan, down 13.51% year-on-year, with a net profit of 28 million yuan, down 83.97% [1] Segment Performance Summary - The skincare segment accounted for 83.70% of total revenue in 2024, while the makeup segment contributed 9.60% [3] - Online sales increased by 10.13% year-on-year, representing 68.21% of total revenue, while offline sales decreased by 10.72% [3] Future Projections - Revenue projections for 2025-2027 are 6.335 billion, 7.260 billion, and 8.491 billion yuan respectively, with net profits of 760 million, 923 million, and 1.057 billion yuan [4] - The company is expected to maintain a stable position in the market while exploring overseas expansion [4]